Question

    Which of the following is a key feature of the gene

    therapy Casgevy, recently approved by the U.S. FDA for sickle cell disease?
    A Utilizes CRISPR gene editing technology. Correct Answer Incorrect Answer
    B Administered as a regular medication over an extended period. Correct Answer Incorrect Answer
    C Specifically designed for individuals under the age of 12. Correct Answer Incorrect Answer
    D Focuses on treating organ failure caused by sickle cell disease. Correct Answer Incorrect Answer
    E Targets individuals primarily from non-Black ethnic backgrounds. Correct Answer Incorrect Answer

    Solution

    The correct answer is A. Casgevy, one of the U.S. FDA-approved gene therapies for sickle cell disease, utilizes CRISPR gene editing technology. This advanced genetic editing approach is notable for its precision and was awarded the Nobel Prize in 2020.

    Practice Next